SAGE Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on development and commercialization of therapies for the treatment of life-threatening, rare central nervous system (CNS) disorders. The Company�s initial product candidates include SAGE-547, SAGE-689 and SAGE-217. The lead product candidate in its SE program, SAGE-547, is an intravenous (IV), agent in Phase 1/2 clinical development as an adjunctive therapy, a therapy combined with therapeutic approaches, for the treatment of super-refractory SE (SRSE). The Company�s follow-on product candidates, SAGE-689 and SAGE-217, utilize similar mechanistic pathways as SAGE-547 and are designed to have pharmaceutical properties which optimize both their non-clinical profiles and potential clinical profiles for the treatment of different stages of SE. SAGE-NCE is being developed as an intravenous therapy, as well as an oral stepdown therapy for status epilepticus and other seizure disorders.